Brief: Mabpharm Says HY Loss Attributable RMB116.8 Mln
26/08/2022 11:35
Aug 26 (Reuters) - Mabpharm Ltd 2181.HK :
* HY LOSS ATTRIBUTABLE RMB116.8 MILLION VERSUS LOSS OF
RMB145.2
MILLION
* HY REVENUE RMB28.8 MILLION VERSUS RMB81.2 MILLION
Source text for Eikon: ID:nHKS9qVrMM
Further company coverage: 2181.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mabpharm
See all newsBrief: Mabpharm Says NMPA Approves CMAB807X (Denosumab Injection) NDA
Brief: Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA
Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
Brief: Mabpharm Says Approval From Drug Regulatory Authority Of Pakistan On Registration Of Core Product,CMAB008
Brief: Mabpharm Says Approval From Indonesian National Agency Of Drug And Food Control Of CMAB008